We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




New Blood Test Platform Simultaneously Measures Over 100 Biomarkers of Alzheimer's Disease

By LabMedica International staff writers
Posted on 11 Oct 2024

Early detection of Alzheimer’s disease-related pathological changes, such as neuroinflammation, impaired brain blood vessel function, and disrupted nerve cell communication, is crucial for enhancing the effectiveness of new infusion treatments and slowing disease progression. More...

Gaining a detailed understanding of molecular changes in individuals at risk for Alzheimer's, before they experience cognitive or memory decline, would help scientists monitor disease progression and eventually establish guidelines for early intervention. However, the current diagnostic methods for Alzheimer’s are not ideal—they are time-consuming, resource-intensive, and can be burdensome for patients who must undergo repeated invasive procedures.

Now, scientists at University of Pittsburgh (Pittsburgh, PA, USA) have independently validated a new blood test platform capable of measuring over 100 biomarkers related to Alzheimer’s disease. This platform could improve clinicians’ ability to capture the complex pathology of Alzheimer’s and streamline early diagnosis. In a proof-of-concept study, the research team tested blood samples from a cohort of 113 cognitively normal older adults living in a financially underserved region of Southwestern Pennsylvania. The samples were sent to Alamar Biosciences (Fremont, CA, USA) for analysis using a novel blood biomarker panel called the NULISAseq CNS Disease 120 Panel. This panel, in addition to measuring classic Alzheimer’s blood biomarkers like phosphorylated tau, amyloid beta, neuroinflammation marker GFAP, and nerve cell damage marker NEFL, also tracks changes in about 120 other proteins related to neurodegenerative diseases.

The performance of the NULISA platform was independently validated against conventional assays for classic Alzheimer’s biomarkers for each sample. Biomarker profiles over two years were also compared with imaging-based measures of amyloid, tau, and neurodegeneration. According to findings published in Molecular Neurodegeneration, the NULISAseq panel identified several biomarkers that correlated with amyloid positivity and changes in amyloid levels over time. These biomarkers, previously associated with Alzheimer’s disease, had typically only been measured in cerebrospinal fluid and included proteins related to neuroinflammation, vascular changes, and impaired nerve cell communication. The researchers expect the platform to track blood biomarker changes over time in individuals both asymptomatic and undergoing treatment. Additionally, they are working on a predictive model that correlates biomarker changes detected by NULISAseq with brain autopsy data and cognitive assessments collected over several years. Their ultimate goal is to identify blood biomarkers that can aid in staging Alzheimer’s disease and predicting its progression, helping inform clinical management and treatment decisions.

“Alzheimer’s disease should not be looked at through one single lens,” said senior author Thomas Karikari, Ph.D., M.Sc., assistant professor of psychiatry at Pitt. “Capturing aspects of Alzheimer’s pathology in a panel of clinically validated biomarkers would increase the likelihood of stopping the disease before any cognitive symptoms emerge.”

Related Links:
University of Pittsburgh
Alamar Biosciences


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Urine Drug Test
Instant-view® Phencyclidine Urine Drug Test
New
Respiratory Syncytial Virus Test
OSOM® RSV Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The LIAISON PLEX® Gram-Positive Blood Culture Assay runs on the on the LIAISON PLEX instrument (Photo courtesy of Diasorin)

Blood Culture Assay Enhances Diagnostic Stewardship Through Targeted Panel Selection

Each year, around 250,000 individuals in the US are diagnosed with bloodstream infections (BSIs). Sepsis caused by these infections carries a mortality rate ranging from 16% to 40%, and any delay in administering... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.